Asset Details
Do you wish to reserve the book?
The clinical effectiveness of sodium-glucose co-transporter-2 inhibitors on prognosis of patients with chronic obstructive pulmonary disease and diabetes
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The clinical effectiveness of sodium-glucose co-transporter-2 inhibitors on prognosis of patients with chronic obstructive pulmonary disease and diabetes
Do you wish to request the book?
The clinical effectiveness of sodium-glucose co-transporter-2 inhibitors on prognosis of patients with chronic obstructive pulmonary disease and diabetes
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The clinical effectiveness of sodium-glucose co-transporter-2 inhibitors on prognosis of patients with chronic obstructive pulmonary disease and diabetes
2025
Overview
Diabetes is common in patients with chronic obstructive pulmonary disease. Sodium-glucose co-transporter-2 inhibitors are effective in treating type 2 diabetes and provide benefits for conditions like cardiovascular and kidney diseases. We use data from multiple institutions and countries to evaluate their role in patients with chronic obstructive pulmonary disease and diabetes. This study includes chronic obstructive pulmonary disease patients with diabetes who are newly prescribed sodium-glucose co-transporter-2 inhibitors or dipeptidyl peptidase-4 inhibitors between January 1, 2013, and August 25, 2024. The primary outcome is all-cause mortality. The results show that the sodium-glucose co-transporter-2 inhibitors group has a lower risk of all-cause mortality compared to the dipeptidyl peptidase-4 inhibitors group (hazard ratio, 0.757; 95% confidence interval, 0.716-0.801). It also shows significantly lower risks of all-cause hospitalization (hazard ratio, 0.864; 95% confidence interval, 0.845-0.884), exacerbation (hazard ratio, 0.924; 95% confidence interval, 0.888-0.962), pneumonia, upper respiratory infections, bronchitis, and major cardiovascular events.
COPD patients are more likely to also have diabetes. Here the authors show that the use of SGLT2 inhibitors was associated with reduced all-cause mortality, hospitalization, acute exacerbations, and pneumonia in patients with COPD and diabetes.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ Aged
/ Chronic obstructive pulmonary disease
/ Diabetes mellitus (non-insulin dependent)
/ Diabetes Mellitus, Type 2 - complications
/ Diabetes Mellitus, Type 2 - drug therapy
/ Diabetes Mellitus, Type 2 - mortality
/ Dipeptidyl-Peptidase IV Inhibitors - therapeutic use
/ Female
/ Glucose
/ Hospitalization - statistics & numerical data
/ Humanities and Social Sciences
/ Humans
/ Kinases
/ Male
/ Obesity
/ Patients
/ Pulmonary Disease, Chronic Obstructive - complications
/ Pulmonary Disease, Chronic Obstructive - drug therapy
/ Pulmonary Disease, Chronic Obstructive - mortality
/ Science
/ Sodium
